CEPI Partners Panacea, THSTI For Pan Beta Coronavirus Vaccines
Panacea’s Dengue, Pneumococcal Vaccines On Track
CEPI will provide up to $12.5m funding for Panacea Biotec and THSTI’s pan-beta coronavirus vaccine candidate, currently in the preclinical stage. Meanwhile, Panacea’s dengue and pneumococcal vaccines are on track for a 2023 launch.
You may also be interested in...
After a chance encounter at a photocopy machine brewed the recipe for Pfizer and Moderna’s success with mRNA vaccines, Dr Drew Weissman has set sights on developing a single-injection therapy for sickle cell anemia.
In the run-up to a major pandemic preparedness summit in London next month, CEPI has announced a new trial aimed at broadening access to vaccines in lower-income countries and has welcomed fresh funding for its plan to cut vaccine development times to 100 days.
Mankind Pharma has licensed Novartis’ heart failure therapy Entresto in India, executive chairman Ramesh Juneja tells Scrip. The privately-owned company has also acquired the generics business of Panacea in India and Nepal for over $255m.